China To Fast-Track Approval For Hemophilia Drugs
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - In an effort to combat the domestic shortage of hemophilia treatments, China's State Food and Drug Administration announced Sept. 18 that it will fast track the approval process for Bayer Healthcare's Kogenate FS (recombinant-clotting factor VIII), which has had an application pending at SFDA since last November